Hyundai Bioscience
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Hyundai Bioscience develops and supplies bioscience-related materials and compounds, with its research and development activities forming a central part of its operations.
It is listed on KOSDAQ, South Korea's technology and small-cap stock exchange. The filing indicates that research and development activity is a prominent component of the business, suggesting the company is at an active development stage for its product pipeline.
Summary is AI-generated and may contain errors · figures from DART filings
Hyundai Bioscience in five facts
What does Hyundai Bioscience do?
Hyundai Bioscience develops and supplies bioscience-related materials and compounds, with its research and development activities forming a central part of its operations.
Where is Hyundai Bioscience listed and in which sector?
Hyundai Bioscience (Korean name: 현대바이오) trades under KRX code 048410 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Materials sector, Chemicals.
How large is Hyundai Bioscience?
Its market capitalisation was US$461.8M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Hyundai Bioscience's latest annual revenue and operating profit?
For fiscal year 2025, Hyundai Bioscience reported revenue of US$2.7M, an operating loss of US$13.7M and a net loss of US$16.7M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was down 76.6% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on securities held by executives/major shareholdersOct 13
- Report on large shareholdings (5% rule) (standard)Oct 13
- [Amended] Half-year report (2026.06)Oct 2
- Report on large shareholdings (5% rule) (standard)Sep 30
- Report on large shareholdings (5% rule) (standard)Sep 16
- Report on securities held by executives/major shareholdersSep 16
- Report on large shareholdings (5% rule) (standard)Sep 8
- Material management matter relevant to investment decisionsSep 4
- Material event report (CB call option holder designated)Capital raise · Jun 23
- Material event report (convertible bonds)
Hyundai Bioscience disclosed convertible bonds to raise US$6.61M, about 1.5% of its market value.
Capital raise · Jun 15 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Hyundai Bioscience reported consolidated results for FY2025: revenue of US$2.44M (−76.6% year on year), an operating loss of US$12.6M (from a profit a year earlier) and a net loss of US$15.4M.
Earnings · Feb 25